Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED · Alpha
██.█% Sign up free to reveal

Viking Therapeutics, Inc. (VKTX) AI Forecast

Our AI ranks Viking Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$VKTX Bullish Signal Full forecast available
Sign Up Free

Viking Therapeutics, Inc. (VKTX) Stock Forecast Sept. 24, 2026

Viking Therapeutics, Inc. (VKTX) AI Stock Price Forecast & Investment Analysis

Viking Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Viking Therapeutics, Inc. (VKTX) - Comprehensive Stock Analysis & Investment Research

Deep dive into Viking Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 24, 2026 (UTC)

Viking Therapeutics, Inc. Investment Summary

When evaluating whether Viking Therapeutics, Inc. (VKTX) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Viking Therapeutics, Inc. (VKTX) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $5 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Viking Therapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Viking Therapeutics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Viking Therapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Viking Therapeutics, Inc.

Sign Up Free
Corporate Identity

Viking Therapeutics, Inc. (Stock Symbol: VKTX) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Viking Therapeutics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Viking Therapeutics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Viking Therapeutics, Inc....

Unlock Full Company Profile

Get complete details about Viking Therapeutics, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Viking Therapeutics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Viking Therapeutics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Viking Therapeutics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Viking Therapeutics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Viking Therapeutics, Inc.'s AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Viking Therapeutics, Inc. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Viking Therapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency
Financial Strength & Leverage

Current ratio of 4.72 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Viking Therapeutics, Inc. (VKTX) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Viking Therapeutics, Inc. stock analysis.

Deep dive into Viking Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Viking Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Viking Therapeutics, Inc.:

P/B Ratio 11.90x
Market Cap $4.86B
EPS $-5.08
Book Value/Share $3.50
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Viking Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Viking Therapeutics, Inc.: An ROE of -131.0% indicates room for improvement in shareholder value creation.

ROE -131.0%
ROA -102.5%
ROIC -135.9%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Viking Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Viking Therapeutics, Inc.: A current ratio of 4.72 indicates strong liquidity.

Current Ratio 4.72x
D/E Ratio 0.28x
Financial Leverage 1.28x
Interest Coverage 86.9x
Working Capital $408M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Viking Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Viking Therapeutics, Inc.:

Operating Cash Flow -$418M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Viking Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Viking Therapeutics, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Viking Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Viking Therapeutics, Inc.:

Income Statement
Operating Income -$560M
Net Income -$534M
R&D Expense $509M
Balance Sheet Highlights (USD millions)
Total Current Assets $518M (99.2% of assets)
Cash & Short-term Investments $126M (24.1% of assets)
Total Liabilities $114M (21.8% of assets)
Short-term Debt $41M (7.8% of assets)
Dividend & Shareholder Information
Shares Outstanding 117M

Latest Viking Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Viking Therapeutics, Inc. (VKTX) stock price and investment outlook.

More news available

Sign up free to read all 11 news articles and stay updated on market developments.

Sign Up Free to Read More

Where VKTX sits on the market map

Explore the map →

Viking Therapeutics, Inc. Industry Peers - Pharmaceutical Preparations

Companies classified under the same SEC industry code as Viking Therapeutics, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
VKTX ██% $4.86B x 11.9x
LLY ██% $1.08T 40.6x 110.2x
JNJ ██% $648.67B 30.8x 7.6x
ONC ██% $539.52B x 104.3x
ABBV ██% $468.43B 74.2x x
MRK ██% $365.34B 115.1x 8.7x
NVS ██% $272.31B x x
GSK ██% $214.26B x x
ABT ██% $180.26B 28.6x 3.5x
PFE ██% $160.62B 37.1x 1.9x
VRTX ██% $130.87B 29.7x 6.5x
BMY ██% $125.63B 13.5x 5.6x
REGN ██% $82.55B 19.1x 2.6x
SNY ██% $50.80B x x
TEVA ██% $45.46B 64.3x 5.9x
ALNY ██% $33.40B x 24.7x
RPRX ██% $33.15B 40.7x 4.9x
ATHE ██% $32.40B x x
TAK ██% $29.93B x x
ZLAB ██% $29.68B x 48.9x
ZTS ██% $29.59B 11.3x 9.4x
ROIV ██% $26.60B x 6.3x
INSM ██% $25.84B x 34.1x
UTHR ██% $20.99B 16.0x 3.3x
VTRS ██% $19.66B x x
JAZZ ██% $15.25B 16.2x 3.2x
ASND ██% $14.30B x x
SMMT ██% $13.12B x 20.8x
BBIO ██% $12.96B x x
CORT ██% $12.81B x 18.2x
HCM ██% $12.54B x 10.1x
BMRN ██% $11.88B x 1.9x
KNSA ██% $11.87B x 19.6x
MDGL ██% $11.85B x 22.6x
ELAN ██% $11.17B x 1.7x
RDY ██% $10.34B x x
AXSM ██% $10.27B x 123.3x
ARWR ██% $9.33B x 20.1x
CYTK ██% $9.13B x x
PTGX ██% $8.98B x 10.7x
PRAX ██% $7.88B x 5.9x
SYRE ██% $7.77B x 7.1x
GPCR ██% $7.71B x 5.7x
ABVX ██% $7.39B x x
IONS ██% $7.30B x 16.6x
ALKS ██% $6.84B x 3.8x
LEGN ██% $6.82B x x
RYTM ██% $6.76B x 65.7x
BLRX ██% $6.68B x x
BLTE ██% $6.67B x 8.7x
AMRX ██% $6.32B x x
LQDA ██% $6.04B x 31.0x
LGND ██% $5.95B 30.2x 6.2x
MIRM ██% $5.80B x x
AMRN ██% $5.64B x 12.7x
TVTX ██% $5.64B x 230.0x
COGT ██% $5.45B x 10.2x
PTCT ██% $5.20B x x
ERAS ██% $5.08B x 14.0x
DNTH ██% $5.07B x 4.3x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Viking Therapeutics, Inc. Stock Forecast

How accurate are Viking Therapeutics, Inc. stock predictions?

A per-ticker accuracy statistic for VKTX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Viking Therapeutics, Inc. stock price forecasts?

Our analysis considers Viking Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Viking Therapeutics, Inc. a good investment in 2026?

Based on our AI analysis, Viking Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Viking Therapeutics, Inc. forecasts updated?

Viking Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 24, 2026.

Want a simpler view of Viking Therapeutics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...